Influencing factors for fasting blood glucose fluctuation trajectories among patients with comorbidity of type 2 diabetes mellitus
YU Dandan1, YANG Jiali1, ZHANG Yaping2, XU Huilin1, HE Dandan1, LI Jun1
1. Minhang District Center for Disease Control and Prevention, Shanghai 201101, China; 2. Minhang District Meilong Community Health Service Center, Shanghai 201102, China
Abstract：Objective To investigate the trajectories of fasting blood glucose fluctuations and their influencing factors among patients with comorbidity of type 2 diabetes mellitus (T2DM), so as to provide the basis for strengthening blood glucose management in this population. Methods In October 2023, data of patients diagnosed with comorbid T2DM from January to October 2021, including demographic information, lifestyle, health status and fasting blood glucose were collected through the chronic disease health management system of Minhang District, Shanghai Municipality. Fasting blood glucose fluctuation trajectories were analyzed by group-based trajectory model established based on fasting blood glucose values from January 2021 to October 2023. Influencing factors of fasting blood glucose fluctuation trajectories among patients with comorbidity of T2DM were analyzed using a multinomial logistic regression model. Results A total of 907 patients with comorbidity of T2DM were enrolled, including 472 males (52.04%) and 435 females (47.96%). There were 652 cases aged ≥65 years, accounting for 71.89%. The group-based trajectory model analysis identified three trajectory groups: a low-level stable group (492 cases, 54.24%), a medium-level stable group (287 cases, 31.64%), and a high-level decreasing group (128 cases, 14.11%). Multinomial logistic regression analysis showed that, compared with the low-level stable group, patients with comorbidity of T2DM who had an education level of junior high school or below (OR=1.420, 95%CI: 1.011-1.995) or college degree or above (OR=2.109, 95%CI: 1.249-3.560), as well as those who engaged in regular exercise (OR=1.387, 95%CI: 1.017-1.893), were more likely to be in the medium-level stable group. Patients with comorbidity of T2DM who were overweight or obese (OR=1.675, 95%CI: 1.116-2.513) or had dyslipidemia (OR=3.195, 95%CI: 1.642-6.216) were more likely to be in the high-level decreasing group. Conclusions From January 2021 to October 2023, the fasting blood glucose levels of patients with comorbidity of T2DM exhibited three fluctuating trajectories: low-level stability, medium-level stability, and high-level decline. Compared with the low-level stable group, the medium-level stable group was mainly influenced by educational level and regular exercise. The high-level decline group was primarily affected by overweight/obesity and dyslipidemia.
[1] WEN Z D,LI Z,CHENG C,et al.National burden and risk factors of diabetes mellitus in China from1990 to 2021:results from the Global Burden of Disease study 2021[J/OL].J Diabetes,2024,16(10)[2025-05-26].https://doi.org/10.1111/1753-0407.70012. [2] 高明妃,胡如英,胡崇高.中国糖尿病死亡流行特征研究进展[J].预防医学,2022,34(7):692-695. GAO M F,HU R Y,HU C G.Research progress on epidemiological characteristics of death of diabetes in China[J].China Prev Med J,2022,34(7):692-695.(in Chinese) [3] 罗雪纯,姜莹莹,吉宁,等.中国6省(直辖市)社区糖尿病患者共病患病情况及其影响因素分析[J].中国公共卫生,2023,39(6):720-724. LUO X C,JIANG Y Y,JI N,et al.Prevalence and influencing factors of multimorbidity among community diabetic patients in six provincial-level administrative divisions of China[J].Chin J Public Health,2023,39(6):720-724.(in Chinese) [4] 李翔,严同,许樟荣.糖尿病和高血压[J].中华糖尿病杂志,2021,13(7):740-745. LI X,YAN T,XU Z R.Diabetes and hypertension[J].Chin J Diabetes Mellit,2021,13(7):740-745.(in Chinese) [5] WENSTEDT E,OLDE E,VOGT L.Sodium handling by the blood vessel wall:critical for hypertension development[J].Hypertension,2018,71(6):990-996. [6] 倪佳英,马晓静,周健.血糖波动异常与糖尿病并发症的研究进展[J].中华糖尿病杂志,2022,14(4):388-392. NI J Y,MA X J,ZHOU J.Research progress of abnormal glycemic variability and diabetic complications[J].Chin J Diabetes Mellit,2022,14(4):388-392.(in Chinese) [7] 师瑞,冯磊,唐灵通,等.糖尿病患者血糖波动评价指标研究进展[J].中华全科医学,2022,20(12):2105-2109. SHI R,FENG L,TANG L T,et al.Research progress on evaluation indicators of blood glucose fluctation in patients with diabetes[J].Chin J Gen Pract,2022,20(12):2105-2109.(in Chinese) [8] 冯国双,于石成,刘世炜.轨迹分析模型在追踪数据分析中的应用[J].中国预防医学杂志,2014,15(3):292-295. FENG G S,YU S C,LIU S W.Application of trajectory analysis model in tracking data analysis[J].Chin Prev Med,2014,15(3):292-295.(in Chinese) [9] 王艾红,尹安春,谢莹莹,等.糖尿病共病管理的研究进展[J].中国护理管理,2018,18(12):1709-1713. WANG A H,YIN A C,XIE Y Y,et al.Research progress in diabetic multimorbidity management[J].Chin Nurs Manag,2018,18(12):1709-1713.(in Chinese) [10] 张晨旭,谢峰,林振,等.基于组轨迹模型及其研究进展[J].中国卫生统计,2020,37(6):946-949. ZHANG C X,XIE F,LIN Z,et al.Group-based trajectory model and its research progress[J].Chin J Health Stat,2020,37(6):946-949.(in Chinese) [11] LENNON H,KELLY S,SPERRIN M,et al.Framework to construct and interpret latent class trajectory modelling[J/OL].BMJ Open,2018,8(7)[2025-05-26].https://doi.org/10.1136/bmjopen-2017-020683 [12] 吴梦怡,胡劲松,黄霜,等.湖南省30岁及以上社区居民高血压、糖尿病、高血脂共病的影响因素分析[J].预防医学,2021,33(2):157-161. WU M Y,HU J S,HUANG S,et al.Influencing factors of comorbidity of hypertension and diabetes among community residents aged 30 and above in Hunan Province[J].China Prev Med J,2021,33(2):157-161.(in Chinese) [13] 官昊宇,覃玉,俞浩,等.空腹血糖长期变异性与2型糖尿病患者心血管疾病死亡风险的前瞻性队列研究[J].中国慢性病预防与控制,2023,31(10):721-726,731. GUAN H Y,QIN Y,YU H,et al.A prospective cohort study on the long-term fasting blood glucose variability and risk of mortality among patients with type 2 diabetes[J].Chin J Prev Contr Chron Dis,2023,31(10):721-726,731.(in Chinese) [14] 周婕,吴延莉,王艺颖,等.BMI水平及动态变化与高血压、糖尿病、血脂异常共病发生风险的前瞻性队列研究[J].中华疾病控制杂志,2023,27(12):1421-1429. ZHOU J,WU Y L,WANG Y Y,et al.Prospective cohort study on the association of body mass index level and its dynamic changes on risks of incident comorbidity among hypertension,diabetes and dyslipidemia[J].Chin J Dis Control Prev,2023,27(12):1421-1429.(in Chinese) [15] MANSI I A,CHANSARD M,LINGVAY I,et al.Association of statin therapy initiation with diabetes progression[J].JAMA Intern Med,2021,181(12):1562-1574.
